EGFR and non-small cell lung carcinoma: The scope of the present study was to evaluate the presence and estimate mutation allele frequencies of EGFR mutations in plasma cfDNA and corresponding CTC-derived gDNA with crystal dPCR in a group of EGFR mutant NSCLC patients under osimertinib therapy before treatment initiation and at progression of disease.